Cytosorbents CorporationCTSONASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P62
Within normal range
vs 2Y Ago
0.8x
Contraction
Streak
1 qtr
Consecutive growthDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 11.64% |
| Q3 2025 | 0.00% |
| Q2 2025 | 0.00% |
| Q1 2025 | -100.00% |
| Q4 2024 | 21.63% |
| Q3 2024 | -8.50% |
| Q2 2024 | -7.85% |
| Q1 2024 | -12.02% |
| Q4 2023 | 14.60% |
| Q3 2023 | 666.03% |
| Q2 2023 | 65.97% |
| Q1 2023 | -6.91% |
| Q4 2022 | -91.67% |
| Q3 2022 | 1298.73% |
| Q2 2022 | -93.29% |
| Q1 2022 | 1143.32% |
| Q4 2021 | -90.51% |
| Q3 2021 | -19.91% |
| Q2 2021 | 25.21% |
| Q1 2021 | 562.64% |
| Q4 2020 | -83.84% |
| Q3 2020 | 5.72% |
| Q2 2020 | 8.79% |
| Q1 2020 | -5.17% |
| Q4 2019 | 5.37% |
| Q3 2019 | 34.18% |
| Q2 2019 | -4.16% |
| Q1 2019 | -25.69% |
| Q4 2018 | 60.63% |
| Q3 2018 | -32.29% |
| Q2 2018 | 40.70% |
| Q1 2018 | -1.85% |
| Q4 2017 | 24.98% |
| Q3 2017 | -2.92% |
| Q2 2017 | 33.29% |
| Q1 2017 | -37.22% |
| Q4 2016 | 93.97% |
| Q3 2016 | -7.81% |
| Q2 2016 | 17.98% |
| Q1 2016 | -6.04% |